Skip to content

Adults: Perimenopause-Related Mood Disorders

Join a Research Study: Enrolling locally from the Washington, D.C. metro region

Menopause and Mood

Researchers are working to understand depression related to the menopause transition. This placebo controlled research study will test whether an experimental medication, Lily compound LYS500307, can prevent depression that may occur after suddenly stopping Estrogen Therapy (ET). This drug acts like estrogen, but has a more limited range of effects.

This 7-week outpatient study at the NIH Clinical Center in Bethesda, MD includes daily ratings on a computer, study medication or placebo, and weekly appointments including routine laboratory tests, blood draws, and clinical questionnaires.

If you are a post-menopausal women age 45 to 65 who struggled with irritability, anxiety, sadness or depression during the perimenopause and your symptoms improved with the use of hormones, please call us to learn more. There is no cost to participate. Compensation is provided. Participants must be free of current psychiatric disorders, psychiatric medications and certain medical conditions.

To find out if you qualify, call 1-301-496-9576 [TTY: 1-866-411-1010].

Join a Research Study: Enrolling locally from the Washington, D.C. metro region

Perimenopause: An Observational Study

This is an observational study for perimenopausal depression in women between the ages of 40 and 60. The purpose of this study is to investigate mood and behavioral changes in the time period surrounding and including menopause. Perimenopausal women with depression symptoms and a control group of healthy perimenopausal volunteers will be compared to one another to identify correlates of the occurrence of depression. Additionally, a group of younger pre-perimenopausal women with normal menstrual cycle functioning will be followed through menopause to observe a possible increase of depressive symptoms around the time of menopause. This is an observational study; volunteers who participate will not receive any new or experimental therapies.

To find out if you qualify, email NIMH or call 1-301-496-9576 [TTY: 1-866-411-1010].